Document:

Advisory and Consulting Agreement

 
Exhibit 4.1

 
Advisory and Consulting Agreement Summary

 

	 	    	 Number of Shares and Options

	 4.1(a)
	    	 9,000,000

	 4.1(b)
	    	 3,000,000

	 4.1(c)
	    	 4,000,000

	 4.1(d)
	    	 100,000

	 4.1(e)
	    	 1,750,000

	 4.1(f)
	    	 5,000,000

	 4.1(g)
	    	 6,000,000

	 4.1(h)
	    	 800,000

	 	    	

	 Total
	    	 29,650,000Amended Consulting Agreement-Blake Ransom

Exhibit 4.1(a) 
 
Amendment No. 2 to Consulting Agreement 
Between Calypte Biomedical Corporation 
and
Blake Ransom 
 
This Agreement amends and modifies the
Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Blake Ransom (“Consultant”) dated November 20, 2002 and is effective as of February 14, 2003. 
 
Whereas, the Company desires to extend the time period during which Consultant
will provide services to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to extending the time for providing such services. 
 
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows:

 

	  	 1.	  	 The term of Consultant’s Consulting Agreement shall be extended and, by virtue of this Amendment, shall terminate on December 31, 2003 rather than November 20,
2003. 

 

	  	 2.	  	 Included specifically as an additional service is a confidential introduction to a high profile celebrity to work with the company to increase awareness of our
products in the marketplace and assist the company from the business side with potential of Board Membership. 

 

	  	 3.	  	 In consideration for the extension and expansion of the services to be performed by Consultant, the Company will immediately grant to Consultant 2,000,000 shares of
its registered common stock. This replaces the 2,100,000 options deferred in Amendment 1. Additionally, the Consultant will receive a warrant to purchase 7,000,000 shares of registered common stock of the Company at $0.05 per share, for an aggregate
purchase price of $350,000. The warrant is immediately exercisable upon grant and will expire on May 14, 2003. All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. All
compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. 

 

	  	 4.	  	 The Consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof each 90 days of this extended contract
within 30 days of the contract’s quarter end. 

 

	  	 5.	  	 All other terms and conditions of the Consultant Agreement dated November 20, 2002 remain unchanged. 

 

	  Consultant:
	  	  	  	  CALYPTE BIOMEDICAL
CORPORATION

	
	  By:
	  	  /s/    BLAKE
RANSOM        

	  	  	  	  By:
	  	  /s/    RICHARD D.
BROUNSTEIN        

	  	  	  Blake Ransom
	  	  	  	  	  	  Richard Brounstein
  Executive Vice President & CFOAmended Consulting Agreement-George Furla

 
Exhibit
4.1(b) 
 
Amendment No. 1 to Consulting
Agreement 
Between Calypte Biomedical Corporation 
and George Furla 
 
This Agreement amends and modifies the Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and George Furla (“Consultant”) dated
November 20, 2002 and is effective as of February 14, 2003. 
 
Whereas, the Company desires to extend the time period during which Consultant will provide services to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to extending the time for providing
such services. 
 
Now therefore, in consideration of the premises
and mutual promises set forth herein, the parties hereto agree as follows: 
 

	  	 1.	  	 The term of Consultant’s Consulting Agreement shall be extended and, by virtue of this Amendment, shall terminate on May 20, 2003 rather than February 20,
2003. 

 

	  	 2.	  	 In consideration for the extension of the services to be performed by Consultant, the Company will immediately grant to Consultant a warrant to purchase 3,000,000
shares of the registered common stock of the Company at $0.05 per share, or an aggregate purchase price of $150,000. All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. The
warrant is immediately exercisable upon grant and will expire on May 14, 2003. 

 

	  	 3.	  	 The Consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof each 90 days of this extended contract
within 30 days of the contract’s quarter end. 

 

	  	 4.	  	 All other terms and conditions of the Consultant Agreement dated November 20, 2002 remain unchanged. 

 

	  Consultant:
	  	  	  	  CALYPTE BIOMEDICAL
CORPORATION

	
	  By:
	  	  /s/    GEORGE
FURLA        

	  	  	  	  By:
	  	  /s/    RICHARD D.
BROUNSTEIN        

	  	  	  George Furla
	  	  	  	  	  	  Richard D. Brounstein
  Executive Vice President & CFOAmended Consulting Agreement-Peter Benz

Exhibit 4.1(c) 
 
Amendment No. 1 to Consulting Agreement 
Between Calypte Biomedical Corporation 
and
Peter Benz 
 
This Agreement amends and modifies the Consulting
Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Peter Benz (“Consultant”) dated January 7, 2003 and is effective as of February 14, 2003. 
 
Whereas, the Company desires to extend the time period during which Consultant
will provide services to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to extending the time for providing such services. 
 
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows:

 

	  	 1.	  	 The term of Consultant’s Consulting Agreement shall be extended and, by virtue of this Amendment, shall terminate on June 30, 2003 rather than February 28,
2003. 

 

	  	 2.	  	 In consideration for the extension of the services to be performed by Consultant, the Company will immediately grant to Consultant a warrant to purchase 4,000,000
shares of the registered common stock of the Company at $0.05 per share, or an aggregate purchase price of $200,000. All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. The
warrant is immediately exercisable upon grant and will expire on May 14, 2003. 

 

	  	 3.	  	 The Consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof each 90 days of this extended contract
within 30 days of the contract’s quarter end. 

 

	  	 4.	  	 All other terms and conditions of the Consultant Agreement dated January 7, 2003 remain unchanged. 

 

	  Consultant:
	  	  	  	  CALYPTE BIOMEDICAL
CORPORATION

	
	  By:
	  	  /s/    PETER BENZ
      

	  	  	  	  By:
	  	  /s/    RICHARD D.
BROUNSTEIN        

	  	  	  Peter Benz
	  	  	  	  	  	  Richard D. Brounstein
  Executive Vice President & CFOAmended Consulting Agreement-Owen Naccarato

Exhibit 4.1(d) 
 
Amendment No. 1 to Consulting Agreement 
Between Calypte Biomedical Corporation 
and
Owen Naccarato 
 
This Agreement amends and modifies the
Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Owen Naccarato (“Consultant”) dated November 1, 2002 and is effective as of February 10, 2003. 
 
Whereas, the Company desires to expand the services the Consultant will
provide to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to this increase in his services. 
 
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows: 
 

	  	 1.	  	 The term of Consultant’s Consulting Agreement shall be not extended and, by virtue of this Amendment, shall still terminate on November 1, 2003; however,

 

	  	 2.	  	 Included specifically as an additional service is the consultants costs regarding the Company’s legal needs relating specifically to its corporate
transactional needs of a February 2003 S-8 filing. 

 

	  	 3.	  	 In consideration for these services to be performed by Consultant, the Company will immediately grant to Consultant 100,000 shares of its registered common stock.
All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. 

 

	  	 4.	  	 All other terms and conditions of the Consultant Agreement dated November 1, 2002 remain unchanged. 

 

	  Consultant:
	  	  	  	  CALYPTE BIOMEDICAL
CORPORATION

	
	  By:
	  	  /s/    OWEN
NACCARATO      

	  	  	  	  By:
	  	  /s/    RICHARD D.
BROUNSTEIN        

	  	  	  Owen Naccarato
	  	  	  	  	  	  Richard Brounstein
  Executive Vice President & CFOAmended Consulting Agreement-Michael Rudolph

Exhibit 4.1(e) 
 
Amendment No. 1 to Consulting Agreement 
Between Calypte Biomedical Corporation 
and
Michael Rudolph 
 
This Agreement amends and
modifies the Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Michael Rudolph (“Consultant”) dated November 20, 2002 and is effective as of February 14, 2003. 
 
Whereas, the Company desires to extend the time period during
which Consultant will provide services to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to extending the time for providing such services. 
 
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto
agree as follows: 
 

	  	 1.	  	 The term of Consultant’s Consulting Agreement shall be extended and, by virtue of this Amendment, shall terminate on July 31, 2003 rather than April 20, 2003.

 

	  	 2.	  	 In consideration for these services to be performed by Consultant, the Company will immediately grant to Consultant 1,750,000 shares of its registered common stock.
All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. 

 

	  	 3.	  	 The Consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof each 90 days of this extended contract
within 30 days of the contract’s quarter end. 

 

	  	 4.	  	 All other terms and conditions of the Consultant Agreement dated November 20, 2002 remain unchanged. 

 

	  Consultant:
	  	  	  	  Calypte Biomedical Corporation

	
	  /s/    MICHAEL RUDOLPH

	  	  	  	  By:
	  	  /s/    RICHARD D.
BROUNSTEIN

	  Michael Rudolph
	  	  	  	  	  	  Richard Brounstein
  Executive Vice President & CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]